Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
- PMID: 16799972
- DOI: 10.1002/hep.21231
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
Abstract
Cirrhosis of the liver is frequently accompanied by complex alterations in the hemostatic system, resulting in a bleeding tendency. Although many hemostatic changes in liver disease promote bleeding, compensatory mechanisms also are found, including high levels of the platelet adhesive protein von Willebrand Factor (VWF). However, conflicting reports on the functional properties of VWF in cirrhosis have appeared in literature. We have measured a panel of VWF parameters in plasma from patients with cirrhosis of varying severity and causes. Furthermore, we assessed the contribution of VWF to platelet adhesion, by measuring the ability of plasma from patients with cirrhosis to support adhesion of normal or patient platelets under flow conditions. VWF antigen levels were strongly increased in patients with cirrhosis. In contrast, the relative collagen binding activity, as well as the relative ristocetin cofactor activity, was significantly lower in patients as compared with controls, indicating loss of function. Accordingly, patients had a reduced fraction of high-molecular-weight VWF multimers. Both strongly elevated and reduced activity and antigen levels of the VWF cleaving protease ADAMTS13 were found in individual patients. Adhesion of either normal or patient platelets to a collagen surface was substantially increased when these platelets were resuspended in plasma of patients with cirrhosis, as compared with control plasma. In conclusion, highly elevated levels of VWF in patients with cirrhosis contribute to the induction of primary hemostasis despite reduced functional properties of the molecule. This phenomenon might compensate for defects in platelet number and function in patients with cirrhosis.
Similar articles
-
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.Hepatology. 2013 Aug;58(2):752-61. doi: 10.1002/hep.26372. Epub 2013 Jul 1. Hepatology. 2013. PMID: 23468040
-
Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.Thromb Haemost. 2018 Aug;118(8):1397-1408. doi: 10.1055/s-0038-1661393. Epub 2018 Jul 4. Thromb Haemost. 2018. PMID: 29972862 Free PMC article.
-
In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma.Thromb Res. 1992 Jan 15;65(2):221-8. doi: 10.1016/0049-3848(92)90242-3. Thromb Res. 1992. PMID: 1579897
-
Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.Blood Coagul Fibrinolysis. 2014 Apr;25(3):206-16. doi: 10.1097/MBC.0000000000000065. Blood Coagul Fibrinolysis. 2014. PMID: 24448155 Free PMC article. Review.
-
Structure and function of snake venom toxins interacting with human von Willebrand factor.Toxicon. 2005 Jun 15;45(8):1075-87. doi: 10.1016/j.toxicon.2005.02.023. Epub 2005 Apr 22. Toxicon. 2005. PMID: 15922776 Review.
Cited by
-
Von Willebrand Factor as a Biomarker for Liver Disease - An Update.J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1047-1060. doi: 10.1016/j.jceh.2023.05.016. Epub 2023 Jun 2. J Clin Exp Hepatol. 2023. PMID: 37975050 Free PMC article. Review.
-
Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients.BMC Gastroenterol. 2020 Aug 17;20(1):271. doi: 10.1186/s12876-020-01413-w. BMC Gastroenterol. 2020. PMID: 32807080 Free PMC article.
-
Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.Thromb Haemost. 2022 Mar;122(3):353-362. doi: 10.1055/a-1515-9529. Epub 2021 Jul 4. Thromb Haemost. 2022. PMID: 34020489 Free PMC article.
-
Hematological abnormalities in liver cirrhosis.World J Hepatol. 2024 Sep 27;16(9):1229-1244. doi: 10.4254/wjh.v16.i9.1229. World J Hepatol. 2024. PMID: 39351511 Free PMC article. Review.
-
Hyponatremia Is Protective Against the Development of Portal Vein Thrombosis in Patients Undergoing Liver Transplant.Transplant Proc. 2019 Jul-Aug;51(6):1880-1886. doi: 10.1016/j.transproceed.2019.05.014. Transplant Proc. 2019. PMID: 31399172 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous